Novartis reports Q2 EPS core $2.42, consensus $2.37

Reports Q2 revenue $14.05B, consensus $14.08B. Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered another strong quarter, with double-digit sales and core operating income growth. We continue to drive strong performance on our ongoing launches for Kisqali, Pluvicto, and Scemblix, demonstrating the replacement power in our portfolio. We also delivered important pipeline milestones including a third positive Phase III readout for Pluvicto in hormone-sensitive prostate cancer and global filings for OAV101 IT in SMA. Our robust balance sheet and confidence in our mid and long-term growth enable us to initiate an up-to $10B share buyback as part of our commitment to balanced capital allocation.”